Quest Diagnostics Incorporated
HealthcareNYSE:DGX · New York Stock Exchange
-$0.77 today
Vol 0.66M · Avg 0.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.8%
avg 16.6%
ROIC
8.4%
avg 9.6%
ROA
6.1%
avg 7.6%
Analysis
ROE is currently the strongest return metric at 13.8% versus its period average of 16.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James E. Davis | Chairman, Chief Executive Officer & President | $3.74M | — | 63 | $132,423.00 | 0.12% |
Sam A. Samad | Executive Vice President & Chief Financial Officer | $1.49M | — | 56 | $33,376.00 | 0.03% |
Catherine T. Doherty | Executive Vice President of Regional Businesses | $1.31M | — | 63 | $67,122.00 | 0.06% |
Karthik Kuppusamy | Senior Vice President of Clinical Solutions | $1.11M | — | 56 | $0.00 | <0.01% |
Michael E. Prevoznik | Senior Vice President & General Counsel | $1.04M | — | 64 | $132,423.00 | 0.12% |
Dan Haemmerle | Interim VP of Investor Relations & VP Finance | — | — | — | — | — |
Garry Clark | Senior Vice President and Chief Marketing & Communications Officer | — | — | — | — | — |
Michael J. Deppe | Senior Vice President, Corporate Controller & Chief Accounting Officer | — | — | 59 | $132,423.00 | 0.12% |
Murali Balakumar | Senior Vice President and Chief Information & Digital Officer | — | — | — | — | — |
Kristin Lee Wallace | Senior Vice President & Chief Compliance Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
36
$38.09M
Net Sentiment
$38.09M
Net selling
Most Active
Plewman Patrick
9 transactions
1–10 of 36
Analysis
Insiders reported 0 buys worth $0.00 and 36 sells worth $38.09M over the last 12 months. That adds up to net selling of $38.09M. Plewman Patrick was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.1% | +7.7% (15yr)5 analysts |
| Revenue | N/A | N/A | +0.5% | +2.9% (15yr)5 analysts |
| Net Income | N/A | N/A | +8.5% | +5.9% (15yr)5 analysts |
| EBIT | N/A | N/A | +5.2% | +2.1% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +12.1% over three years. Forward estimates point to EPS at +7.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.35B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
Incyte Corporation
NASDAQ:INCY
$21.68B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.35B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Who manages DGX?
Quest Diagnostics Incorporated (DGX) lists 10 active executives. The top listed executive is Michael E. Prevoznik, Senior Vice President & General Counsel.
Are DGX insiders buying or selling?
Recent insider activity shows net selling of $9.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.